文献速递系统性红斑狼疮

血清IgG2抗体多组分在系统性红斑狼疮与狼疮肾炎中的横断面分析

Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该横断面研究纳入1052例SLE患者(479例伴LN、573例不伴LN)及PAPS、RA、UCTD对照,检测抗核小体、抗细胞内抗原等IgG2抗体。结果显示IgG2抗体面板对SLE/LN vs 健康人高度鉴别,抗ENO1和抗H2A IgG2可区分LN与SLE并与SLEDAI高值相关。

要点

  • 抗dsDNA和抗C1q IgG2比普通IgG更敏感识别低-中滴度SLE患者。
  • 抗ENO1和抗H2A IgG2可区分LN与SLE,LN阳性率分别为63%和67%,SLE均为3%。
  • 上述抗体阳性与高SLEDAI值相关,与其他风湿病仅有微小差异。

核心结论

  • 致病性IgG2抗体是SLE/LN的特异性标志,与其他风湿病仅有少量重叠。
  • 高水平的抗ENO1和抗H2A IgG2与SLE活动指数相关,并可区分仅限肾脏并发症的SLE患者与其他SLE患者。

研究设计与样本

  • 横断面分析纳入1052例SLE患者(伴LN 479例、不伴LN 573例),从症状开始不同时间招募。
  • 对照包括原发性APS 24例、RA 24例和UCTD 96例。
  • 采用非商业技术检测抗核小体(dsDNA、Histone2A、Histone3)、抗细胞内抗原(ENO1)、抗膜联蛋白A1和抗C1q的IgG2。

主要发现

  • 血清IgG2面板对SLE/LN vs 健康受试者高度鉴别。
  • 抗dsDNA和抗C1q IgG2血清水平在识别低-中增量SLE患者时比IgG(Farr放射免疫分析/商业检测)更敏感。
  • 抗ENO1和抗H2A IgG2血清阳性可区分LN与SLE(ROC T0-12个月)。
  • T0-1个月时抗ENO1和抗H2A IgG2高水平分别见于63%和67%的LN患者,而SLE患者均为3%。
  • 上述每种抗体血清阳性与高SLEDAI值相关,LN/SLE与其他风湿病之间仅存在微小差异。

关键数值与推荐

  • 抗ENO1 IgG2高水平在LN中占63%,在SLE中占3%。
  • 抗H2A IgG2高水平在LN中占67%,在SLE中占3%。

临床怎么用

  • 抗dsDNA和抗C1q IgG2可能提高低-中滴度SLE的识别敏感性。
  • 抗ENO1和抗H2A IgG2可用于区分LN与无肾脏受累的SLE,并与SLEDAI活动指数相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Serum anti-dsDNA and anti-nucleosome IgGs have been proposed as signatures for SLE and LN in limited numbers of patients. We sought to show higher sensitivity and specificity of the same antibodies with the IgG2 isotype and included IgG2 antibodies vs specific intracellular antigens in the analysis. METHODS: A total of 1052 SLE patients with (n = 479) and without (n = 573) LN, recruited at different times from the beginning of symptoms, were included in the study. Patients with primary APS (PAPS, n = 24), RA (RA, n = 24) and UCTD (UCTD, n = 96) were analysed for comparison. Anti-nucleosome (dsDNA, Histone2A, Histone3), anti-intracellular antigens (ENO1), anti-annexin A1 and anti-C1q IgG2 were determined by non-commercial techniques. RESULTS: The presence in the serum of the IgG2 panel was highly discriminatory for SLE/LN vs healthy subjects. Serum levels of anti-dsDNA and anti-C1q IgG2 were more sensitive than those of IgGs (Farr radioimmunoassay/commercial assays) in identifying SLE patients at low-medium increments. Of more importance, serum positivity for anti-ENO1 and anti-H2A IgG2 discriminated between LN and SLE (ROC T0-12 months), and high levels at T0-1 month were detected in 63% and 67%, respectively, of LN, vs 3% and 3%, respectively, of SLE patients; serum positivity for each of these was correlated with high SLEDAI values. Minor differences existed between LN/SLE and the other rheumatologic conditions. CONCLUSION: Nephritogenic IgG2 antibodies represent a specific signature of SLE/LN, with a few overlaps with other rheumatologic conditions. High levels of anti-ENO1 and anti-H2A IgG2 correlated with SLE activity indexes and were discriminatory between SLE patients limited to the renal complication and other SLE patients. TRIAL REGISTRATION: The Zeus study was registered at https://clinicaltrials.gov, NCT02403115.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bruschi M, Moroni G, Sinico RA, et al. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology (Oxford). 2021. PMID: 33374003. doi:10.1093/rheumatology/keaa767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。